Approving cancer treatments based on endpoints other than overall survival: an analysis of historical data using the PACE Continuous Innovation Indicators™ (CII)

BACKGROUND: There is an active debate about the role that endpoints other than overall survival (OS) should play in the drug approval process. Yet the term ‘surrogate endpoint’ implies that OS is the only critical metric for regulatory approval of cancer treatments. We systematically analyzed the re...

Descripción completa

Detalles Bibliográficos
Autores principales: Brooks, Neon, Campone, Mario, Paddock, Silvia, Shortenhaus, Scott, Grainger, David, Zummo, Jacqueline, Thomas, Samuel, Li, Rose
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699106/
https://www.ncbi.nlm.nih.gov/pubmed/29167693
http://dx.doi.org/10.7573/dic.212507

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699106/
https://www.ncbi.nlm.nih.gov/pubmed/29167693
http://dx.doi.org/10.7573/dic.212507

Ejemplares similares